Pramodini Medicare IPO Review, Financial Analysis & Valuation
In-depth editorial analysis, statutory financial disclosures, and peer valuation metrics to help you evaluate if the Pramodini Medicare IPO is good or bad.
Business Overview
Pramodini Medicare Limited, founded in 2000, is one of the leading diagnostic services providers in India across radiology, clinical laboratory, and nuclear medicine segments. Its service portfolio includes radiology services such as MRI, CT scans, X-ray, ultrasound with colour Doppler, mammography, DEXA scan, and interventional radiology; clinical laboratory services including haematology, microbiology, immunology, pathology, and biochemistry; and nuclear medicine services such as PET-CT, SPECT, and nuclear therapy.
Financial Performance
Peer Comparison & Valuation
Compare the valuation of Pramodini Medicare against its listed industry peers to determine if the issue price is justified.
Should you apply for the Pramodini Medicare IPO?
Determining whether the Pramodini Medicare IPO is good or bad requires evaluating the company's financial growth trajectory, the sector's macroeconomic tailwinds, and the premium demanded by the promoters in the price band.
- Review the PAT (Profit After Tax) margins in the financials table above to ensure profitability is not artificially inflated just before the IPO.
- Examine the P/E Ratio in the peer comparison section. A lower P/E relative to industry peers may indicate an undervalued issue.
- Monitor the QIB subscription data on the final day, as heavy institutional buying is a strong indicator of smart-money confidence.